Argireline

Trade name for acetyl hexapeptide-8, a synthetic six-residue mimic of the SNAP-25 N-terminus used as a topical cosmetic ingredient and marketed as a non-toxic, botulinum-toxin-like approach to expression wrinkles.

Also referenced as: Acetyl Hexapeptide-8, Acetyl Hexapeptide-3, Acetyl Hexapeptide-8 Amide, AH8, AH-8

What is Argireline?

Argireline is the trade name (originated by Lipotec, now part of Lubrizol) for acetyl hexapeptide-8, a synthetic peptide of six amino acids with an acetylated N-terminus and an amidated C-terminus: Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, molecular weight about 889 Da. The sequence was designed to copy the N-terminal region of SNAP-25, one of the three proteins that assemble into the SNARE complex that docks and fuses neurotransmitter vesicles, and the same protein that botulinum toxin type A cleaves. It has been a commercial cosmetic ingredient since about 2001 and is one of the most widely used peptides in anti-wrinkle skin care, which is how it reaches the research-peptide market: as a topical raw material and in pre-formulated serums, usually listed alongside Matrixyl, SNAP-8, and Leuphasyl.

How it works

• Competitive interference with SNARE assembly. The hexapeptide was rationally designed to mimic the N-terminal domain of SNAP-25 so that it competes with the native protein for a position in the SNARE complex; in the original design paper it inhibited neurotransmitter release in vitro with a potency described as similar to botulinum neurotoxin type A but a much lower maximal effect, which the authors attributed to interference with the formation or stability of the SNARE complex rather than proteolytic cleavage (Blanes-Mira et al., International Journal of Cosmetic Science, 2002;24(5):303-310).
• Proposed downstream effect on expression lines. The working hypothesis is that fewer vesicle-fusion events at the neuromuscular junction mean less acetylcholine release and less contraction of the facial muscles that fold the skin into dynamic wrinkles; later authors also describe interference with catecholamine release (Wang et al., American Journal of Clinical Dermatology, 2013). This is a mechanism established in cell systems; whether it operates after topical application has not been demonstrated.
• The delivery problem. Acetyl hexapeptide-8 is hydrophilic, zwitterionic, and comparatively large for passive skin permeation. In an FDA laboratory study using a 10% oil-in-water emulsion on human cadaver skin in diffusion cells for 24 hours, most of the dose was washed from the surface, 0.22% was recovered from the stratum corneum, about 0.01% from the epidermis, and none from the dermis or receptor fluid, with no metabolite detected in any layer (Kraeling et al., Cutaneous and Ocular Toxicology, 2015;34(1):46-52).
• Formulation and analog work aimed at that problem. A water-in-oil-in-water multiple emulsion significantly increased penetration into porcine ear skin compared with simple oil-in-water and water-in-oil vehicles (Hoppel et al., European Journal of Pharmaceutical Sciences, 2015;68:27-35). Ester-modified analogs designed to suppress the zwitterion were tested in human cadaver skin: two of the three analogs permeated better than the parent peptide in vitro, and in an assay of glutamate release from stem-cell-derived neurons one of those two was the most active compound in the series while the other was the least (Lim et al., Scientific Reports, 2018;8:1596). None of these delivery-enhanced versions has been tested in a controlled human efficacy study.

Research status

Acetyl hexapeptide-8 is a cosmetic ingredient, not a marketed drug. The human evidence consists of small topical cosmetic studies plus two NIH-sponsored trials of a medical use that ended without further development.

Cosmetic efficacy studies. The original report (Blanes-Mira et al., International Journal of Cosmetic Science, 2002) describes healthy women volunteers applying a 10% oil-in-water emulsion for 30 days, with skin-topography analysis showing wrinkle depth reduced by up to 30%; the abstract gives no subject count and describes no vehicle-control arm. The best-controlled published study is Wang et al., American Journal of Clinical Dermatology, 2013;14(2):147-153: 60 Chinese subjects randomized 3:1 to argireline or placebo applied to periorbital wrinkles twice daily for 4 weeks. Subjective total anti-wrinkle efficacy was 48.9% in the argireline group against 0% with placebo, and silicone-replica roughness parameters fell significantly in the argireline group (p < 0.01) with no significant change on placebo. A placebo arm that shows no response at all is unusual for a cosmetic wrinkle study. Raikou et al., Journal of Cosmetic Dermatology, 2017;16(2):271-278 assigned 24 volunteers to acetyl hexapeptide-3 alone, tripeptide-10 citrulline alone, both, or neither for 60 days, reporting a significant fall in transepidermal water loss with the hexapeptide and an anti-wrinkle effect for the combination. Two registered cosmetic studies never reported results: a Mahidol University trial labeled phase 3 (NCT01381484; 70 participants, 10% gel versus placebo twice daily for 3 months, completed September 2009) and a University of California, Davis split-face study of a 10% lotion for the appearance of oily skin (NCT02597777; 14 participants, completed February 2016).

Blepharospasm (NIH). The National Institute of Neurological Disorders and Stroke ran a phase 1/2 trial (NCT00942851; July 2009 to October 2010, with BCN Peptides, a Lipotec group company, as collaborator and supplier of the cream) in 24 patients with blepharospasm who received their usual botulinum toxin injections and then applied a 0.005% acetyl hexapeptide-8 cream or placebo to the eyelids. Published as Lungu et al., European Journal of Neurology, 2013;20(3):515-518, the study was FDA-monitored under investigational new drug application 105,646; the time for symptoms to return to baseline on the Jankovic Blepharospasm Rating Scale was about 3.7 months on active cream versus 3.0 months on placebo, a trend that did not reach significance, with 4 of 12 active-arm patients showing extended control of 3.3 to 7.1 months and no significant adverse events. The follow-up phase 2 trial of 0.025% and 0.05% creams (NCT01750346; started November 2012) was terminated after enrolling 8 participants, with a completion date of May 2015 and no reason stated; the registry results list means of 6 and 7 points at 2 months for the 0.05% and 0.025% arms (n = 2 each) against 4.33 for placebo (n = 3), numbers too small to interpret, and one serious adverse event each in the 0.05% and placebo arms. No further clinical development of acetyl hexapeptide-8 for any medical indication has been registered as of November 2026.

Reviews and recent work. Lum et al., Journal of Drugs in Dermatology, 2025;24(4):e31-e32 reviewed 10 human studies (302 women and 10 men in total) and found that all reported reductions in wrinkle or scar prominence but that statistical significance was inconsistent, that half of the studies tested multi-ingredient formulations in which the peptide’s contribution cannot be isolated, and that the comparison with botulinum toxin rests on potency, toxicity, and cost figures rather than any head-to-head trial. Zdrada-Nowak et al., International Journal of Molecular Sciences, 2025;26(12):5722 reached a similar verdict, naming poor stratum-corneum permeability as the main obstacle and the mechanism of any topical muscle-relaxing effect as poorly understood. Zhu et al., International Journal of Cosmetic Science, 2026;48(5):913-925 (a L’Oréal study of a serum combining acetyl hexapeptide-8 with four other actives) reported static-wrinkle improvements of 35% to 69% at 12 weeks in 50 subjects, but the design cannot isolate the hexapeptide’s contribution.

Regulatory and safety review. The Expert Panel for Cosmetic Ingredient Safety concluded that acetyl hexapeptide-8 amide is safe in cosmetics in the present practices of use at concentrations up to 0.005%, and that the available data are insufficient to support safety above that level (Johnson et al., International Journal of Toxicology, 2025;44(2_suppl):54S-63S). The FDA has never approved the molecule as a drug; its only drug-regulatory footprint is the investigational new drug application that covered the two NIH blepharospasm trials.

Common dosage forms

Argireline is a topical-only compound in practice. Cosmetic ingredient suppliers sell it as an aqueous peptide solution containing a low percentage of active for formulators to add to creams, serums, and emulsions; finished consumer products declare it on the ingredient panel as acetyl hexapeptide-8 and most often appear as serums, eye creams, and face creams. Research vendors list it as lyophilized powder in the tens-to-hundreds-of-milligrams range labeled for topical use, as pre-diluted topical solutions, and in blends with Leuphasyl, SNAP-8, or Matrixyl. Published studies used oil-in-water emulsions, gels, lotions, and creams at concentrations ranging from 0.005% in the first blepharospasm trial to 10% in the cosmetic efficacy studies. It is not sold in the injectable vial format used for metabolic and recovery peptides.

Key considerations

• Regulatory status. Acetyl hexapeptide-8 is a cosmetic ingredient with no FDA drug approval, no marketing application, and no compounding pathway; its only formal US safety review is the Cosmetic Ingredient Review conclusion covering concentrations up to 0.005%. The Research Market status reflects that the molecule has no US approval and no active registered clinical development as of November 2026, the two NIH-sponsored blepharospasm trials having ended in 2010 and 2015 without a successor program.
• A concentration gap sits at the center of the evidence. The published wrinkle studies that report benefit used 10% formulations, several orders of magnitude above the 0.005% ceiling the Cosmetic Ingredient Review found adequately supported, while the one medical trial run at 0.005% showed only a non-significant trend. Marketed products and research-vendor solutions span this range, and results from one concentration do not transfer to another.
• Mechanism and delivery remain disconnected. SNARE interference is established in cell systems, but the FDA permeation study found no peptide in the dermis after a 24-hour 10% application, and the neuromuscular junctions that the mechanism targets lie below the dermis. The 2025 reviews treat the route from topical application to muscle relaxation as unexplained; any benefit seen in short cosmetic studies may reflect hydration, barrier, or other effects rather than neuromodulation.
• Evidence is small, short, and largely industry-adjacent. The largest placebo-controlled study enrolled 60 subjects for 4 weeks and reported a 0% placebo response; the original 30-day study describes no vehicle control; a 70-participant phase-3-labeled trial and a split-face oily-skin study were completed but never reported; and several positive studies tested multi-peptide blends. No published study has compared the peptide head-to-head with botulinum toxin.
• Naming confusion is common. Argireline, acetyl hexapeptide-8, acetyl hexapeptide-8 amide (the name used in the Cosmetic Ingredient Review), and the older label acetyl hexapeptide-3 all refer to the same molecule, and older papers and ingredient lists still use the -3 name. It is distinct from SNAP-8 (acetyl octapeptide-3, a two-residue-longer analog), from other numbered hexapeptides with different sequences and targets such as acetyl hexapeptide-1, -30, and -38, and from the supplier’s later “Argireline Amplified” ingredient, which the supplier describes as a different sequence sold under the same acetyl hexapeptide-8 INCI name. “Argireline” is a trademark for a specific ingredient preparation; research-market listings carrying the name are generic acetyl hexapeptide-8 of varying provenance.
• Safety signals. Topical use has been well tolerated in published studies: the first blepharospasm trial recorded only minor, self-limiting eyelid irritation in two patients per arm, and the design paper reported no in vivo oral toxicity or primary irritation at high doses. There are essentially no published data on injected or other non-topical routes, and the Expert Panel’s safe-use conclusion does not extend above 0.005%.